Air Pollution and Lung Cancer - The IASLC Position Statement

Lung cancer is a complicated disease with many causes. Among them are tobacco smoke, radon, and asbestos. However, one largely overlooked cause is the relationship between air pollution and lung cancer.

There have been numerous basic, translational, and epidemiological studies demonstrating that air pollution causes approximately 14% of lung cancer cases worldwide. A substantial body of evidence regarding air pollution and risk of mortality comes from survival studies of cohorts that evaluated air pollution-mortality associations while controlling for important risk factors. Several epidemiological studies have shown that people living in areas with high air pollution are more likely to die of lung cancer than those who do not, including people who have never smoked.

Outdoor air pollution and its major component, particulate matter, have been rated as Group 1 carcinogens by the International Agency for Research on Cancer. Although many components of outdoor ambient air pollution are harmful to one’s health, one of the worst culprits is Particulate Matter 2.5 (PM2.5). Chronic, persistent exposure to PM2.5 can exacerbate such diseases as chronic obstructive pulmonary disease and can cause lung cancer, even in people who have never smoked. Each 10µ/m³ increase in PM2.5 is estimated to be associated with a 14% increase in lung cancer mortality. Additionally, the increase in the number of hot days from the accumulation of atmospheric greenhouse gases can lead to an increase in ground-level ozone, increasing smog, decreasing air quality, and exacerbation of respiratory illnesses.

The International Association for the Study of Lung Cancer is the world’s largest professional organization dedicated to the prevention and treatment of lung cancer. As an international organization of lung cancer professionals and advocates serving people in both developed and developing countries, and vulnerable individuals living in areas with heavy air pollution, we support advocacy for clean air, and urge all health care organizations and relevant legislative bodies to support the IASLC policy statement.

IASLC:

- Urges all relevant local, national, and international legislative bodies to restrict air emission targets to the lowest levels as recommended by the World Health Organization
- Encourages health organizations to advocate for reducing fossil fuel emissions and for clean, sustainable energy
- Encourages collaboration among health organizations on climate advocacy and environmental sustainability
- Encourages health organizations to disinvest themselves from fossil fuel companies.
- Supports further research into the pathophysiological and carcinogenetic effects of PM2.5 and other pollutants on human health
- Urges all health care organizations to lower their carbon footprint at national and international meetings by encouraging virtual participation and decreasing the amount of paper and waste generated by industry and non-industrial partners.
References


Authors

Joan H. Schiller, MD, FACP
University of Virginia, Adjunct Professor
Lung Cancer Research Foundation

Christine Berg, MD
Oncology Screening Consultant

Stephen Lam, MD
BC Cancer & the University of British Columbia

Charu Aggarwal, MD, MPH
University of Pennsylvania

Eric Bernicker, MD
Houston Methodist Hospital Cancer Center

Paolo Boffetta, MD, MPH
Stony Brook Cancer Center

Milena Cavic, PhD
Institute for Oncology and Radiology of Serbia
Jonathon Dowell, MD
UT Southwestern Medical Center

Regan Duffy, MD, MPH
Providence Cancer Center

Ivy Elkins, MBA
EGFResisters

David Gerber, MD
UT Southwestern Medical Center

Rudolf Huber, MD, PhD
University of Munich

Samuel A. Kareff, MD, MPH
University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital

Stephen Liu, MD
Georgetown University

Corey Langer, MD, FACP
University of Pennsylvania

Laura Mezquita, MD, PHD
Hospital Clinic of Barcelona

Renelle Myers, MD
BC Cancer & the University of British Columbia

Jacquelyn E. Nixon
Citizens for Radioactive Radon Reduction

Kurt Oettel, MD
Gunderson Clinic

Sandeep Patel, MD
University of California, San Diego

Nathan Penell, MD, Phd
Cleveland Clinic

M. Patricia Rivera, MD
University Of North Carolina

Upal Basu Roy, PhD, MPH
LUNGevity Foundation
Rachel Sanborn, MD
Earle A. Chiles Research Institute, Providence Cancer Institute

David Spigel, MD
Sarah Cannon Research Institute

Anne Traynor, MD
University of Wisconsin, Madison

Vamsi Velcheti, MD
New York University

Howard (Jack) West, MD
City of Hope Cancer Center

Jun Zhang, MD, PhD
University of Kansas Medical Center